Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.12 and traded as high as $1.12. Cortexyme shares last traded at $1.07, with a volume of 96,565 shares trading hands.
Cortexyme Stock Performance
The business has a 50 day simple moving average of $1.16 and a 200-day simple moving average of $1.12. The firm has a market cap of $32.26 million, a price-to-earnings ratio of -0.36 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Stories
- Five stocks we like better than Cortexyme
- How to Use the MarketBeat Excel Dividend Calculator
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Stock Market Sectors: What Are They and How Many Are There?
- Hilton Demonstrates Asset Light is Right for Investors
- What Are the U.K. Market Holidays? How to Invest and Trade
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
